SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-053247
Filing Date
2024-04-29
Accepted
2024-04-29 06:01:11
Documents
8
Period of Report
2024-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm244019-3_def14a.htm DEF 14A 1001733
2 GRAPHIC bc_neticome-4c.jpg GRAPHIC 59152
3 GRAPHIC bc_versustsr-4c.jpg GRAPHIC 63649
4 GRAPHIC lg_bioxceltherapeutics-4clr.jpg GRAPHIC 17438
5 GRAPHIC px_24bioxcelproxy1pg01-bw.jpg GRAPHIC 287680
6 GRAPHIC px_24bioxcelproxy1pg02-bw.jpg GRAPHIC 215055
7 GRAPHIC sg_javierrodriguez-bw.jpg GRAPHIC 16008
8 GRAPHIC sg_petermueller-bw.jpg GRAPHIC 5852
  Complete submission text file 0001104659-24-053247.txt   1879007
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38410 | Film No.: 24886350
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)